- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bausch + Lomb Corp(BLCO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BLCO
11/18/2026: BLCO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Bausch + Lomb Corp is a major global eye health company providing a diversified portfolio of contact lenses, consumer eye care products, ophthalmic pharmaceuticals, and surgical equipment. Its main business strengths include a century-old trusted brand legacy, a broad multi-segment product footprint, and steady top-line revenue growth. The primary investment story centers on expanding high-margin silicone hydrogel contact lenses and advancing specialty pharmaceutical pipelines for conditions like dry eye. However, the company faces intense competition from larger profitable peers, a heavy debt load, and historical challenges in translating strong sales into consistent net profitability. The stock suits growth-oriented or momentum investors willing to monitor execution milestones, though conservative dividend seekers should note the absence of cash payouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While top-line revenue growth is steady, inconsistent net profitability makes it a mixed choice for pure growth seekers. |
| Momentum investor | Strong fit while signal remains positive | Positive quarterly guidance lifts and product milestone updates can trigger sharp upward price momentum. |
| Value investor | Mixed fit | The stock trades at reasonable earnings multiples, but bottom-line losses require careful fundamental evaluation. |
| Dividend investor | Weak fit | Bausch + Lomb does not currently pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Debt leverage, volatile earnings, and intense sector competition generate too much risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock frequently reacts sharply to earnings reports, regulatory updates, and guidance adjustments. |
| Valuation risk | Medium | Valuation multiples remain sensitive to whether management can successfully expand operating margins over time. |
| Competition risk (Alcon and Cooper Companies) | High | Stiff competition from larger, highly profitable peers can pressure market share and pricing power. |
| Business quality | Medium | Strong brand recognition and high gross margins are tempered by elevated SG&A expenses and historical net losses. |
| Dividend income | Low / none | The company distributes no dividend payouts to shareholders. |
| Execution risk | Medium / high | Successfully integrating major product acquisitions like XIIDRA and scaling pipeline treatments is critical for financial turnaround. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.50B USD | Price to earnings Ratio - | 1Y Target Price 21.93 |
Price to earnings Ratio - | 1Y Target Price 21.93 | ||
Volume (30-day avg) 963.5K shares | Beta 0.52 | 52 Weeks Range 14.44 - 21.40 | Updated Date 11/18/2026 |
52 Weeks Range 14.44 - 21.40 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 50.0%
- Active BUY / eligible
- 3 / 6
- 30-Day BUY Count Change
- +1
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -24.3% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Vision Care | Contact lenses (such as INFUSE and Ultra) and consumer eye care products (like Biotrue solutions and Ocuvite vitamins). | This is the largest segment, driven by everyday consumer purchases and recurring contact lens usage. |
| Pharmaceuticals | Prescription and generic eye drops and therapies addressing dry eye, glaucoma, and inflammation (such as XIIDRA and Vyzulta). | Provides higher-margin specialty medical products prescribed by eye care specialists. |
| Surgical | Cataract equipment, intraocular lenses (IOLs), vitreoretinal surgical tools, and consumables. | Supplies hospital operating rooms and surgical centers with advanced equipment and procedural hardware. |
| Geographic Operations | Commercial sales spanning the United States, Europe, Asia, and international markets. | Global diversification buffers the company against localized economic downturns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate 0.21 | Actual 0.34 |
Profitability
Profit Margin -2.05% | Operating Margin (TTM) 9.41% |
Management Effectiveness
Return on Assets (TTM) 2.29% | Return on Equity (TTM) -1.58% |
Valuation
Trailing PE - | Forward PE 18.15 | Enterprise Value 12.11B | Price to Sales(TTM) 1.38 |
Enterprise Value 12.11B | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 2.23 | Enterprise Value to EBITDA 15.42 | Shares Outstanding 357.50M | Shares Floating 46.39M |
Shares Outstanding 357.50M | Shares Floating 46.39M | ||
Percent Insiders 87.12 | Percent Institutions 11.74 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

